CN103405430A - Applications of corynoxine - Google Patents

Applications of corynoxine Download PDF

Info

Publication number
CN103405430A
CN103405430A CN2013103949131A CN201310394913A CN103405430A CN 103405430 A CN103405430 A CN 103405430A CN 2013103949131 A CN2013103949131 A CN 2013103949131A CN 201310394913 A CN201310394913 A CN 201310394913A CN 103405430 A CN103405430 A CN 103405430A
Authority
CN
China
Prior art keywords
nuoxin
blood pressure
corynoxine
hypertension
hypertensive
Prior art date
Application number
CN2013103949131A
Other languages
Chinese (zh)
Inventor
不公告发明人
Original Assignee
苏州天南星生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州天南星生物科技有限公司 filed Critical 苏州天南星生物科技有限公司
Priority to CN2013103949131A priority Critical patent/CN103405430A/en
Publication of CN103405430A publication Critical patent/CN103405430A/en

Links

Abstract

The invention belongs to the technical field of medicines, and relates to applications of Chinese traditional herb monomer chemical corynoxine for resisting hypertension, and a corynoxine-containing composition used for preventing and treating hypertension.

Description

The purposes of Ke Nuoxin
Technical field
The invention belongs to medical technical field, relate to the purposes of Ke Nuoxin.
Background technology
Hypertension is modal chronic disease, is also the topmost risk factor of cardiovascular and cerebrovascular disease, and apoplexy, myocardial infarction, heart failure and chronic kidney disease are its major complications.Both domestic and external facts have proved, hypertension are the diseases that can prevent and control, reduce hyperpietic's blood pressure level, can obviously reduce apoplexy and the events of heart attack, significantly improve patient's life quality, effectively reduce the disease burden.Hypertensive hazardness and patient's blood pressure level mutually outside the Pass, also depend on the situation of the other diseases of simultaneous other cardiovascular risk factors, target organ damage and merging.Therefore in hypertensive definition and classification, by hypertensive diagnostic criteria fix on systolic pressure >=140mmHg and (or) diastolic pressure >=90mmHg, according to blood pressure level, be divided into normally, outside normal high value blood pressure and 1,2,3 grade of hypertension, also according to the other diseases of risk factor, target organ damage and merging simultaneously, carry out risk stratification simultaneously.
Prevalence of Hypertension raises with age growth; Women's prevalence before climacteric, a little less than the male, but raises rapidly after climacteric, even higher than the male; High latitude cold district prevalence is higher than the warm area of low latitudes, and high altitude localities is higher than low altitude area; Relevant with dietary habit, salt and saturated fat are taken in higher, and mean blood pressure level and prevalence are also higher.Population of China hypertension is popular two relatively outstanding features: from south to the north, Prevalence of Hypertension is and increases progressively trend; Between different nationalities, Prevalence of Hypertension also has some differences, the national prevalence of living in the north or highlands is higher, the national prevalence of living in south or non-highlands is lower, this species diversity may be relevant with geographical environment, life style etc., not yet finds between various nationalities to have obvious genetic background difference.
Treating hypertensive main purpose is to reduce to greatest extent cardiovascular and cerebrovascular vessel morbidity and dead total danger, therefore require the doctor in the hypertensive while for the treatment of, intervene the clinical disease that all reversibility cardiovascular risk factors of patient, target organ damage and merging exist.For general hyperpietic's blood pressure lowering target, be below 140/90mmHg, for high-risk patients such as complication with diabetes or nephropathy, blood pressure should be taken the circumstances into consideration to be down to more low-level in the tolerant situation of patient.
Common depressor has: the Chinese medicine for lowering high blood pressure medicines such as calcium antagonists, RAS depressant, receptor,β blocking agent, diuretic antihypertensive medicine, Niuhuang Jiangya sheet.
Summary of the invention
The object of the present invention is to provide the antihypertensive purposes of Ke Nuoxin (CAS:6877-32-3).
Further, be used to preventing and treating the compositions of the hypertensive Ke Nuoxin of containing.
Ke Nuoxin can effectively reduce blood pressure, and controls preferably the systolic pressure of spontaneous hypertensive rat (SHR).
The specific embodiment
Embodiment 1. Ke Nuoxin hypotensive activities
10~13 week spontaneous hypertensive rats in age (SHR) are pressed to the blood pressure grouping, and concrete dosage is in Table 1, and oral administration is the arteria caudalis pressure measurement after 7 days.
Statistical analysis: measurement data mean+SD Mean t check between relatively employing group of data between two groups.Take P<0.05 is the significance standard.
Result: Ke Nuoxin can effectively reduce the SHR rat blood pressure, and relatively there were significant differences (P<0.05) with model control group, in Table 1.
The impact of table 1. Ke Nuoxin successive administration on the SHR rat blood pressure
With model control group, compare P<0.05.

Claims (2)

1. the purposes of Ke Nuoxin, is characterized in that: the purposes of Ke Nuoxin antihypertensive function.
2. the purposes of Ke Nuoxin according to claim 1, is characterized in that: be used to preventing and treating the compositions of the hypertensive Ke Nuoxin of containing.
CN2013103949131A 2013-09-03 2013-09-03 Applications of corynoxine CN103405430A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2013103949131A CN103405430A (en) 2013-09-03 2013-09-03 Applications of corynoxine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013103949131A CN103405430A (en) 2013-09-03 2013-09-03 Applications of corynoxine

Publications (1)

Publication Number Publication Date
CN103405430A true CN103405430A (en) 2013-11-27

Family

ID=49598505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013103949131A CN103405430A (en) 2013-09-03 2013-09-03 Applications of corynoxine

Country Status (1)

Country Link
CN (1) CN103405430A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101342259A (en) * 2008-06-18 2009-01-14 沈阳药科大学 Method for extracting alkaloid valid target from hooked uncaria leaf, with hook stem branch or full grass and uses thereof
CN101862304A (en) * 2010-07-23 2010-10-20 贵州百花医药股份有限公司 Uncaria sustained-release tablet and preparation method thereof
CN102311435A (en) * 2011-07-05 2012-01-11 南京泽朗农业发展有限公司 Preparation method for high purity rhynchophylline
WO2012126390A1 (en) * 2011-03-23 2012-09-27 Hong Kong Baptist University Autophagy inducing compound and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101342259A (en) * 2008-06-18 2009-01-14 沈阳药科大学 Method for extracting alkaloid valid target from hooked uncaria leaf, with hook stem branch or full grass and uses thereof
CN101862304A (en) * 2010-07-23 2010-10-20 贵州百花医药股份有限公司 Uncaria sustained-release tablet and preparation method thereof
WO2012126390A1 (en) * 2011-03-23 2012-09-27 Hong Kong Baptist University Autophagy inducing compound and use thereof
CN102311435A (en) * 2011-07-05 2012-01-11 南京泽朗农业发展有限公司 Preparation method for high purity rhynchophylline

Similar Documents

Publication Publication Date Title
Smith et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo‐controlled studies
Nunez et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure
CN102824545B (en) Blood sugar-reduction traditional Chinese medicine composition
NZ606595A (en) Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease
WO2004096249A1 (en) A composition containing radix codonopsis pilosulae and radix astragali and hedysari, method of producing it and use thereof
CN103816280B (en) Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition
US20080305189A1 (en) Treatment of aspirin resistance with radix salviae miltiorrhizae, its extract and composition
CN102102079B (en) Blood pressure-reducing table vinegar and preparation method thereof
CN103239493A (en) Pharmaceutical composition for reducing blood sugar and preparation method thereof
CN103845348B (en) 20 (R)-ginsenoside Rg3s application in preparation dysmenorrhea medicine
US20150050375A1 (en) Total flavone extract of flower of abelmoschus manihot l. medic and preparation method thereof
CN103055169B (en) External use plaster for treating hypertensive disease
CN103328983A (en) Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury
CN101011522A (en) Chinese traditional medicine for treating cardiopathy
CN108064164A (en) Neuregulin is used to prevent, treat or postpone the method and composition of the heart failure of ejection fraction reservation
CN104000197A (en) Health care product or medicine composition capable of relieving fatigue and preparation method and purpose thereof
CN103937655B (en) White spirit with anti-fatigue function and production method thereof
Khanji et al. Tako-Tsubo syndrome after trastuzumab—an unusual complication of chemotherapy for breast cancer
WO2014201637A1 (en) Compound preparation for treating cervical spondylosis with radiculopathy and preparation method therefor
CN101417132B (en) Use of medicine combination comprising carvedilol and angiotensin II recipient antagonist in preparing medicine for treating kidney disease
CN102488815A (en) Buccal tablet for reducing blood sugar
Cui et al. Effects of qili qiangxin capsule on AQP2, V2R, and AT1R in rats with chronic heart failure
CN103920025A (en) Pharmaceutical composition for treating hypertension and application thereof
CN104147154A (en) Antihypertensive traditional Chinese medicament
Oguzturk et al. Complete atrioventricular block caused by mad honey intoxication

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131127